FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 840 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC MOST POPULAR Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT... February 26, 2026 For People with Cancer, Are Steroids the Best Treatment for Breathing... October 25, 2022 Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... February 9, 2023 Five Fraction SBRT Noninferior to Moderately Fractionated Image-Guided Radiotherapy for Patients... November 7, 2024 Load more HOT NEWS Percentage of Cancer Patients Who Are Eligible for and Respond to... How Cancer Survivorship Has Changed Over 25 Years: An Expert Perspective Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy... Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who...
